Abstract: A medication adherence and container system for informing a patient when it is time to and not to take medication; for storing medicine information sheets with the medicine containers; and holding the medicine containers in arranged clusters, having containers and caps which interact between each other as switches with the electrical circuits provided. The electrical circuits have a timing device which can be set for a predetermined elapsed time and provides a continuous signal, such as a colored light, during the running of said predetermined time to indicate “not to take medication” and then provides a different signal, such as a different colored light, when the predetermined time has lapsed to indicate “take medication” and continues that signal until being reset upon breaking the electrical circuit between cap and container and restarting the timing device on closing the circuit between cap and container for measuring another predetermined elapsed time.

Abstract: The present invention provides a dental material, a dental material composition and a dental restorative material that exhibit small polymerization shrinkage particularly during curing and are producible at low cost on the industrial scale. The dental material of the present invention includes a specific urethane (meth)acrylic compound represented by Formula (1) described below.

Abstract: A single-paste, self-adhesive dental curable composition that has strong self-adhesion to biological hard tissues (such as enamel and dentin of teeth) and good color tone adaptability suitable for use for aesthetic restoration is provided. A dental curable composition contains: an inorganic particle (A) with an average grain size in the range of 0.1 to 50 ?m; an inorganic particle (B) with an average grain size in the range of 0.1 to 50 ?m; a polymerizable monomer (C); and a polymerization catalyst (D). The refractive index na of the inorganic particle (A) and the refractive index nb of the inorganic particle (B) meet the relationship of na>nb. A cured resin material (E), which is obtained by curing a polymerizable composition containing the polymerizable monomer (C) and the polymerization catalyst (D), has a refractive index ne that meets the relationship (1): 0?|na?ne|<0.01?ne?nb?0.05??(1).

Abstract: A dispersible moist wipe used to clean urine and fecal matter from the skin. The wetting solution is an oil-in-water emulsion containing silicone oil. Phase separation is prevented with one or more gums, propylene glycol alginate, and a Gemini surfactant or phosphate ester.

Abstract: The present application directed to a unique combination of surfactants in concentrated form. In particular certain combinations of alkyl polyglucosides and polyglyceryl fatty acid esters when combined yield a cleansing concentrate which can be diluted to form tear free or mild cleanser.

Abstract: The present invention is related to an aqueous conditioning composition for hair comprising at least one alkyl ether alkyl amine or alkyl ether alkyl quaternary amine and at least one compound selected from fatty acid fatty alcohol esters and arylated silicones.

Abstract: An agent for the oxidative dyeing of keratin fibers, in particular human hair, includes in a cosmetic carrier (a) at least one first alkyl glucoside of formula (I) set forth herein, in which R1 is an unbranched or branched, saturated or unsaturated C20-C28 alkyl group and n is an integer from 1 to 10, (b) at least one second alkyl glucoside of formula (II) set forth herein, in which R2 is an unbranched or branched, saturated or unsaturated C8-C18 alkyl group and m is an integer from 1 to 10, (c) at least one oxidation dye precursor of the developer type, and d) at least one oxidation dye precursor of the coupler type.

Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-Yp-Zq-R2??(I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, and in processes of treatment and/or care of the skin, hair and/or mucous membranes, in particular in the aging and photoaging of the skin, are described.

Abstract: TRPV1 inhibitory peptides and a composition for skin-aging prevention and wrinkle improvement comprising the same as an active ingredient are described. The TRPV1 inhibitory peptide of the present subject matter inhibits the expressions of MMP and proinflammatory cytokines induced by UV exposure and reduces skinfold thickness and intracellular Ca2+ influx, so that it can be effectively used as an active ingredient of the composition for skin-aging prevention, wrinkle improvement, skin-whitening, or alleviating inflammation, irritation, or pain.

Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.

Abstract: This invention provides a Chinese medicinal formula comprising Atractylodis Macrocephalae Rhizoma, Glycyrrhizae Radix et Rhizoma, Angelicae sinensis Radix, Paeoniae Radix Alba and Poria for skin care. It further relates to a method for preparing bioactive fraction of this formula and to the applications of the bioactive fraction in skin-whitening and anti-skin-aging.

Abstract: The present invention relates to a synthetic solid bar cleanser formulated to clean human skin. More particularly, the present invention relates to synthetic solid cleanser formulations which have pH of about 5.5, the same as human skin, and yet which perform similarly, or superior, to traditional soap.

Abstract: The present invention relates to compositions and methods for treating sialic acid deficiencies comprising extended release formulations.

Abstract: Topical compositions having as the active ingredient a lipid, fatty acid ester, natural wax, sterol, or combinations thereof referred to herein as “lipophilic vehicle” or “LV” and methods of use, have been developed for the amelioration or prevention of pain or the sequelae of pain. The composition may be in the form of an ointment, cream, gel, lotion, spray, foam, paste, patch, suspension or dispersion. The composition is variably effective to treat visceral, somatic and neuropathic pain both acute and chronic as well as muscle pain and stiffness and joint pain and stiffness.

Abstract: Composition for application to skin comprising a biocide or combination of biocides (such as chlorhexidine, halogenated phenols, quaternary ammonium compounds; povidone-iodine; zinc pyridinethione; alcohols etc.) and at least one transcutaneous vehicle (for example alkyl methyl sulfoxides, alkyl pyrrolidones, glycols, glycol ethers and glycol esters) effective to convey the biocide to a sub epidermal “resident” micro-organism. Also a method for preparing a patient for surgery comprising the step of treating an area of the patient's skin at, and in the surrounding the vicinity of, the site of an intended surgical incision with a composition effective to kill more than 93% of both “transient” and “resident” micro-organisms.

Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine in a matrix at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate matrix formulations are provided within biodegradable polymers, this pain relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Abstract: A stable and/or synergistic pharmaceutical composition including: a) predinisolone metasulfobenzoate (PMSB) or its acceptable salts, preferably prednisolone metasulfobenzoate sodium and b) 5-ASA, derivatives or pharmaceutically acceptable salts thereof, which is suitable for rectal administration.

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: The invention relates to certain nicotine chewing gums that provide for a high rate of buccal absorption and high plasma concentrations, in particular over the first 10 minutes after administration, in a subject willing to quit smoking.

Abstract: A suspension and a cake composition are provided in which agglomeration of the active ingredient that is caused when silicone oil and/or silicone oil derivative is contained therein can be suppressed without a special treatment, such as sonication. The suspension contains, in a dispersion medium, an active ingredient of a specific mean primary particle size, and silicone oil and/or silicone oil derivative. The cake composition contains an active ingredient of a specific mean particle size, and silicone oil and/or silicone oil derivative.

Abstract: The present invention relates to liquid or semi-solid pharmaceutical compositions, more specifically to aqueous pharmaceutical suspension or semi-solid paste containing natural mineral clays as active ingredients. These compositions are particularly useful for the treatment of acute and chronic diarrhea.

Abstract: The present invention provides new amino lipids and a convenient method for synthesizing these compounds. These (cationic) amino lipids have good properties as transfection agents. The method is an economic versatile two step synthesis allowing the preparation of various amino lipids thus leading to the assembly of a combinatorial library of transfection agents. Moreover, the present invention provides lipid particles (liposomes) containing said amino lipids and their use for delivering bioactive agents into cells. The invention encompasses also the use of lipid particles containing the cationic amino lipids as medicament.

Abstract: The invention relates to the field of pharmaceutics, pharmaceutical nano-technology and pharmacology and concerns a system for delivering biologically active agents into an organism, the system comprising a nano-diamond with a particle size of 2-10 nm, the surface of said particles being modified by chlorine with a chlorine content of up to 14%, and to a method for producing said system.

Abstract: A poorly soluble drug containing microsphere with improved bioavailability, an oral formulation comprising the same, and a method of preparing the same are provided, wherein the poorly soluble drug containing microsphere is a solid dispersion wherein the poorly soluble drug is dispersed in the water-soluble polymer carrier in a noncrystalline form by spray drying, thus increasing bioavailability of the poorly soluble drug.

Abstract: Dietary calcium supplements comprising highly bioavailable forms of calcium carbonate and methods of using these calcium carbonate forms to improve calcium balance, strengthen bones, and prevent, treat, and/or ameliorate bone loss associated with osteoporosis are provided.

Abstract: The present invention features a tablet containing at least one first material, at least one second material, and at least one pharmaceutically active agent, wherein: (a) the first material is a dielectric water-containing material (i) containing from about 1 to about 5 percent, by weight, of bound water and (ii) having a dielectric loss, when measured at a density of between 0.15 and 0.5 g/cc, of from about 0.05 to about 0.7; and (b) the second material (i) having a water solubility from about 20 to about 400 g per 100 g of water at 25° C., (ii) having a dielectric loss, when measured at a density between 0.5 and 1 g/cc, of less than about 0.05.

Abstract: The present invention provides an intraorally rapidly disintegrating tablet that can be formed using an ordinary apparatus, that has hardness with no practical problem and that disintegrates rapidly with good feeling in the oral cavity. The present invention is intraorally rapidly disintegrating tablet produced by compression molding of a granule coated with a disintegrant, in which the granule contains a disintegrant also inside thereof and a drug except ambroxol hydrochloride inside and/or outside thereof.

Abstract: A controlled release particle includes a core formed by suspension polymerization of a core ingredient component containing an antibiotic compound and a first polymerizable vinyl monomer, and containing a first polymer of the first polymerizable vinyl monomer and the antibiotic compound present in the first polymer; and a shell formed by suspension polymerization of a second polymerizable vinyl monomer having affinity with water of the same or higher than that of the first polymerizable vinyl monomer, containing a second polymer obtained from the second polymerizable vinyl monomer, and covering the core.

Abstract: The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduced side effects such as nausea and irritation.

Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) and other CNS stimulant responsive conditions include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by an extended release.

Abstract: The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.

Abstract: The invention is generally a skin treatment for managing skin conditions ranging from scars, including keloids, to burns and wrinkles. The skin treatment may comprise of several components including a cleansing solution, a silicone elastomer, and a mineral powder that may be utilized to treat and camouflage the affected skin. In one embodiment, a cleansing component is used to prime a skin area, cleansing and treating the area so that a silicone component can heal the skin.

Abstract: The present invention relates to a Java ginger extract which is prepared from Java ginger as a starting material and aimed at a concentrate as an objective (concentrate including solid matter) obtained from a solute. The starting material or the products on any of the steps in which the objective is manufactured from the starting material is heated or exposed to sunlight. In relation to a peak area ratio on high-performance liquid chromatography (HPLC), the peak area ratio (D/M ratio) of a phenyl butenoid dimer represented by the following formula (1) to a monomer represented by the following formula (2) is 0.6 or higher. An intake/dose of the Java ginger extract can be decreased by increasing a content of a phenyl butenoid dimer with an NGF-like action.

Abstract: Disclosed herein is a method of promoting sustained survival, sustained regeneration, in a lesioned mature neuron, sustained compensatory outgrowth in a neuron, or combinations thereof. The method comprises contacting the lesioned mature neuron with an effective amount of an inhibitor of PTEN and an effective amount of an inhibitor of SOCS3 to thereby promote survival and/or regeneration and/or compensatory outgrowth of the neuron. Therapeutic methods of treatment of a subject with a neuronal lesion by administration of a therapeutically effective amount of an inhibitor of PTEN and a therapeutically effective amount of an inhibitor of SOCS3, are also disclosed, as are pharmaceutical compositions and devices for use in the methods.

Abstract: The present invention provides drug therapy formulations. In some embodiments, the present invention provides combinations of pharmaceutical agents (e.g., stimulant and non-stimulant), pharmaceutical formulations (e.g., nanoparticualte, non-nanoparticualte, etc.), and release profiles (e g, immediate release, delayed release, sustained release, etc.) to provide therapeutic benefit with reduced side effects.

Abstract: The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

Abstract: The present invention relates to a skin or surface disinfectant composition with broad spectrum antimicrobial activity comprising one or more essential oil (and/or one or more component thereof) and one or more fruit acid. The compositions of the invention may be used as non-toxic alternatives to conventional disinfectants or may be added to other antimicrobial agents to enhance their activity. The invention provides effective alternatives to harsher products which may be particularly useful in personal care and household products and where children and/or pet exposure may be a concern.

Abstract: Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.

Abstract: The invention relates to small molecules having biological and therapeutic activity. Particularly, the invention relates to small molecules having lipolytic and anti-adipogenic activity. Two examples of such molecules are 4-methyl-2-(octanoylamino) pentanoic acid and N-isopentyloctanamide. The invention further relates to methods of preventing or treating skin conditions such as cellulite using small molecules having lipolytic and anti-adipogenic activity.

Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising fumarate esters are described.

Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.

Abstract: This invention relates to riluzole for use in the treatment or prevention of adverse effects associated with the administration of anticancer agents having neurotoxic effects, such as, for example, platinum salts, taxanes and periwinkle alkaloids.

Abstract: Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.

Abstract: The invention relates to a composition comprising: a complex of delphinidin and a sulfoalkyl ether-?-cyclodextrin and/or delphinidin and the salts thereof as a first component; and a tumour-necrosis factor related apoptosis-inducing ligand (TRAIL) as a second component, for use in the treatment of malignant melanoma.

Abstract: The present invention relates to a pharmaceutical composition containing flavone compound as an active ingredient for treating obesity, and more specifically to a pharmaceutical composition for preventing or treating obesity and a dietary composition for preventing or reducing obesity containing 5,7-dimethoxyflavone or 5,7,4?-trimethoxyflavone. The compound according to the present invention inhibits adipogenesis, and reduces expression of the key transcription factors (SREBP1c and C/EBP) related to lipogenesis and of enzyme proteins (FAS and ACC) related to adipogenesis, and thus is effective in preventing or treating obesity.

Abstract: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention.

Abstract: Methods and compositions provided herein relate to the treatment of cancer. In some embodiments, the compositions have utility in the treatment of cancers including glioblastoma multiforme and lung cancer.

Abstract: A method for producing a patch comprising a support layer and an adhesive agent layer comprises: a mixture preparation step of mixing asenapine or a pharmaceutically acceptable salt thereof with sodium acetate whose particle diameter D50 at a cumulative volume of 50% in a particle diameter distribution is 40 to 1000 ?m, in such a manner that the sodium acetate and sodium diacetate generated from the sodium acetate have a particle diameter D50 of 10 ?m or smaller, thereby obtaining a mixture containing the sodium diacetate and the asenapine or pharmaceutically acceptable salt; and an adhesive-agent-layer formation step of forming the adhesive agent layer comprising the sodium diacetate, the asenapine or pharmaceutically acceptable salt, and a pressure-sensitive adhesive base agent, by using an adhesive agent layer composition obtained by mixing the mixture with the pressure-sensitive adhesive base agent.

Abstract: The present invention is directed to compounds of the Formula I: as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases. The invention furthermore relates to specific diastereomers and enantiomers of the compounds, to processes for preparing compounds of the Formula I, to their potential use for the therapy and prophylaxis of the above-mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.